ReviewOncogene2000
Met receptor tyrosine kinase: enhanced signaling through adapter proteins.
Review in Oncogene, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 151 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
151 citing papers in PubMed, 2 syntheses or guidelines pooled it, 412 citations in OpenAlex.
- Diagnosis and Prognostic Significance of c-Met in Cervical Cancer: A Meta-Analysis.Disease markers · 2016Pooled it
- Host-pathogen systems biology: logical modelling of hepatocyte growth factor and Helicobacter pylori induced c-Met signal transduction.BMC systems biology · 2008Pooled it
- Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease.Stem cell research & therapy · 2014Trial
- The lysosomal cysteine protease cathepsin L promotes stemness and multidrug resistance of non-small cell lung cancer by targeting HGF activator.Molecular and cellular biochemistry · 2026Article
- The Potential Hepatocyte Differentiation Targets and MSC Proliferation by FH1.Journal of cellular and molecular medicine · 2025Article
- Piperlongumine overcomes osimertinib resistance via governing ubiquitination-modulated Sp1 turnover.JCI insight · 2025Article
- Advances in clinical research of MET exon 14 skipping mutations in non-small cell lung cancer.Journal of cancer research and clinical oncology · 2025Review
- CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside.Molecular cancer · 2024Review
- Spatiotemporal regulation of the hepatocyte growth factor receptor MET activity by sorting nexins 1/2 in HCT116 colorectal cancer cells.Bioscience reports · 2024Article
- Article
- Dual-targeting therapy against HER3/MET in human colorectal cancers.Cancer medicine · 2023Article
- Hepatocyte Growth Factor Enhances Antineoplastic Effect of 5-Fluorouracil by Increasing UPP1 Expression in HepG2 Cells.International journal of molecular sciences · 2022Article
- Receptor tyrosine kinase MET ligand-interaction classified via machine learning from single-particle tracking data.Molecular biology of the cell · 2022Article
- Impact of the flame retardant 2,2'4,4'-tetrabromodiphenyl ether (PBDE-47) in THP-1 macrophage-like cell functionFrontiers in immunology · 2022Article
- Opportunities and challenges of targeting c-Met in the treatment of digestive tumors.Frontiers in oncology · 2022Review
- 3D Ultrasound-Guided Photoacoustic Imaging to Monitor the Effects of Suboptimal Tyrosine Kinase Inhibitor Therapy in Pancreatic Tumors.Frontiers in oncology · 2022Article
- Design, Synthesis, and Biological Evaluation of [1,2,4]triazolo[4,3-Frontiers in chemistry · 2022Article
- Prognostic relevance of longitudinal HGF levels in serum of patients with ovarian cancer.Molecular oncology · 2021Article
- Magnetofection In Vivo by Nanomagnetic Carriers Systemically Administered into the Bloodstream.Pharmaceutics · 2021Review
- Article
91 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Met receptor tyrosine kinase is the prototypic member of a small subfamily of growth factor receptors that when activated induce mitogenic, motogenic, and morphogenic cellular responses. The ligand for Met is hepatocyte growth factor/scatter factor (HGF/SF) and while normal HGF/SF-Met signaling is required for embryonic development, abnormal Met signaling has been strongly implicated in tumorigenesis, particularly in the development of invasive and metastatic phenotypes. Following ligand binding and autophosphorylation, Met transmits intercellular signals using a unique multisubstrate docking site present within the C-terminal end of the receptor. The multisubstrate docking site mediates the binding of several adapter proteins such as Grb2, SHC, Crk/CRKL, and the large adapter protein Gab1. These adapter proteins in turn recruit several signal transducing proteins to form an intricate signaling complex. Analysis of how these adapter proteins bind to the Met receptor and what signal transducers they recruit have led to more substantial models of HGF/SF-Met signal transduction and have uncovered new potential pathways that may be involved into Met mediated tumor cell invasion and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.